Switch theme
Sign up to access all valuation multiples
Zhejiang Nhu Co Ltd is a China-based company engaged in the manufacture and sales of pharmaceuticals, health protection products, pharmaceutical intermediates, fragrances, food additives and feed additives. The company's active pharmaceutical ingredient products cover various areas such as Cardiovascular, Anti-AIDS, Anti-cancer and Anti-bacterial with key products such as Latamoxef Sodium, Flomoxef Sodium, Hydrochloride Moxifloxacin, Artemisinin series, Calcium Keto acid series, Vitamin A/E/D3 and coenzyme Q10 and others. The other business areas are Aroma chemicals, Polymers, and Nutrition. The organization markets its products in China and internationally.
1994
4.3K+
LTM Revenue $3.1B
LTM EBITDA $1.3B
$9.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zhejiang NHU has a last 12-month revenue (LTM) of $3.1B and a last 12-month EBITDA of $1.3B.
In the most recent fiscal year, Zhejiang NHU achieved revenue of $3.0B and an EBITDA of $1.3B.
Zhejiang NHU expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zhejiang NHU valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.1B | XXX | $3.0B | XXX | XXX | XXX |
| Gross Profit | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| Gross Margin | 41% | XXX | 42% | XXX | XXX | XXX |
| EBITDA | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EBITDA Margin | 41% | XXX | 44% | XXX | XXX | XXX |
| EBIT | $995M | XXX | $1.0B | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | 33% | XXX | XXX | XXX |
| Net Profit | $835M | XXX | $815M | XXX | XXX | XXX |
| Net Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Zhejiang NHU's stock price is CNY 22 (or $3).
Zhejiang NHU has current market cap of CNY 67.4B (or $9.4B), and EV of CNY 67.6B (or $9.4B).
See Zhejiang NHU trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.4B | $9.4B | XXX | XXX | XXX | XXX | $0.27 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Zhejiang NHU has market cap of $9.4B and EV of $9.4B.
Zhejiang NHU's trades at 3.1x EV/Revenue multiple, and 7.2x EV/EBITDA.
Equity research analysts estimate Zhejiang NHU's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zhejiang NHU has a P/E ratio of 11.2x.
See valuation multiples for Zhejiang NHU and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.4B | XXX | $9.4B | XXX | XXX | XXX |
| EV (current) | $9.4B | XXX | $9.4B | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | 7.3x | XXX | 7.2x | XXX | XXX | XXX |
| EV/EBIT | 9.4x | XXX | 9.4x | XXX | XXX | XXX |
| EV/Gross Profit | 7.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 11.2x | XXX | 11.5x | XXX | XXX | XXX |
| EV/FCF | 9.5x | XXX | 12.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZhejiang NHU's last 12 month revenue growth is 11%
Zhejiang NHU's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.1M for the same period.
Zhejiang NHU's rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zhejiang NHU's rule of X is 68% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Zhejiang NHU and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 41% | XXX | 44% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | 33% | XXX | XXX | XXX |
| Rule of 40 | 46% | XXX | 55% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 68% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zhejiang NHU acquired XXX companies to date.
Last acquisition by Zhejiang NHU was XXXXXXXX, XXXXX XXXXX XXXXXX . Zhejiang NHU acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Zhejiang NHU founded? | Zhejiang NHU was founded in 1994. |
| Where is Zhejiang NHU headquartered? | Zhejiang NHU is headquartered in China. |
| How many employees does Zhejiang NHU have? | As of today, Zhejiang NHU has 4.3K+ employees. |
| Is Zhejiang NHU publicy listed? | Yes, Zhejiang NHU is a public company listed on SHE. |
| What is the stock symbol of Zhejiang NHU? | Zhejiang NHU trades under 002001 ticker. |
| When did Zhejiang NHU go public? | Zhejiang NHU went public in 2004. |
| Who are competitors of Zhejiang NHU? | Similar companies to Zhejiang NHU include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Zhejiang NHU? | Zhejiang NHU's current market cap is $9.4B |
| What is the current revenue of Zhejiang NHU? | Zhejiang NHU's last 12 months revenue is $3.1B. |
| What is the current revenue growth of Zhejiang NHU? | Zhejiang NHU revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Zhejiang NHU? | Current revenue multiple of Zhejiang NHU is 3.0x. |
| Is Zhejiang NHU profitable? | Yes, Zhejiang NHU is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zhejiang NHU? | Zhejiang NHU's last 12 months EBITDA is $1.3B. |
| What is Zhejiang NHU's EBITDA margin? | Zhejiang NHU's last 12 months EBITDA margin is 41%. |
| What is the current EV/EBITDA multiple of Zhejiang NHU? | Current EBITDA multiple of Zhejiang NHU is 7.3x. |
| What is the current FCF of Zhejiang NHU? | Zhejiang NHU's last 12 months FCF is $985M. |
| What is Zhejiang NHU's FCF margin? | Zhejiang NHU's last 12 months FCF margin is 31%. |
| What is the current EV/FCF multiple of Zhejiang NHU? | Current FCF multiple of Zhejiang NHU is 9.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
